Clinical Usefulness of Red Cell Distribution Width/Albumin Ratio to Discriminate 28-Day Mortality in Critically Ill Patients with Pneumonia Receiving Invasive Mechanical Ventilation, Compared with Lacate/Albumin Ratio: A Retrospective Cohort Study

Jong Hwan Jeong,† Manbong Heo,† Seung Jun Lee, Yi Yeong Jeong, Jong Deog Lee, and Jung-Wan Yoo*

Citation: Jeong, J.H.; Heo, M.; Lee, S.J.; Jeong, Y.Y.; Lee, J.D.; Yoo, J.-W. Clinical Usefulness of Red Cell Distribution Width/Albumin Ratio to Discriminate 28-Day Mortality in Critically Ill Patients with Pneumonia Receiving Invasive Mechanical Ventilation, Compared with Lacate/Albumin Ratio: A Retrospective Cohort Study. Diagnostics 2021, 11, 2344. https://doi.org/10.3390/diagnostics11122344

Abstract: The value of the red cell distribution width (RDW) is associated with prognosis in critically ill patients. A simplex combined index—the RDW/albumin ratio—has been proposed for the prediction of mortality, as has the lactate/albumin ratio. The aim of this study was to evaluate the clinical utility of the RDW/albumin ratio regarding 28-day mortality in critically ill patients with pneumonia. Clinical data of critically ill patients with pneumonia who were hospitalized in the medical intensive care unit from May 2018 to December 2020, and received invasive mechanical ventilation (IMV), were reviewed retrospectively. The values of RDW, lactate, and albumin measured at the time of IMV, were used for the index calculations. Of the 234 patients, the median age was 76 years, and 74.2% were male. The 28-day mortality rate was 47.3%. The median RDW/albumin ratio was significantly higher in non-survivors than survivors at 28 days (5.8 vs. 4.9, \(p < 0.001\)). A higher RDW/albumin ratio was significantly associated with increased 28-day mortality (odds ratio [OR] 1.338, 95% confidence interval [CI] 1.094–1.637, \(p = 0.005\)). The area under the receiver operating curve (AUROC) was 0.694 (95% CI: 0.630–0.758, \(p < 0.005\)) to discern 28-day mortality without significant difference, compared with that of the lactate/albumin ratio. Our data suggest that high RDW/albumin ratio has a similar predictability to the lactate/albumin ratio in critically ill patients with pneumonia receiving IMV.

Keywords: red cell distribution width; albumin; lactate; pneumonia; invasive mechanical ventilation; mortality

1. Introduction

Pneumonia is a common infection of the lower respiratory tract, and contributes to a substantial economic healthcare burden [1,2]. It is caused by diverse microbes including bacteria, viruses or fungi [3], and commonly accompanied by severe hemodynamically and respiratory-compromised conditions [4,5]. These devastating complications generally make intensive care unit (ICU) admission inevitable for performing life-saving interventions, such as fluids, vasopressor infusion, or invasive mechanical ventilation and so forth [6,7]. Despite this intensive care, the mortality rate in these conditions remains high, ranging from 10% to 50% [5,8–10].

Inflammation induced by host-pathogen interaction is the major pathogenesis for severe conditions secondary to pneumonia [11–13]. Therefore, it is important to ameliorate
inflammation in tandem with treatment of causative pathogens using optimal antiviral, bacterial, or fungal agents. It is important to identify or repurpose new or known inflammatory single or combined indexes that can predict the clinical outcomes of critically ill patients with pneumonia, hospitalized in the ICU, because lung inflammation is a major contributor to adverse outcomes [14,15].

Red cell distribution width (RDW) is easily measured from venous blood and routinely shown in complete blood count profiles. RDW is a marker to reflect the variability in red blood cell size and its increase is called anisocytosis. Several conditions such as inflammatory reactions are associated with increased RDW [16]. The RDW has been related to outcomes of various clinical conditions [17–20], as well as in critical illness [21]. Elaborated mechanisms for increased RDW in critically ill conditions, including severe pneumonia or sepsis, remain to be determined, but inflammation increases RDW value by stimulating production of circulating premature erythrocytes from bone marrow [22]. Furthermore, excessive reactive oxygen species (ROS) under oxidative stress also stimulate erythropoiesis, leading to anisocytosis and increased RDW [23]. There are a few studies showing that the combination of RDW and other feasible markers in clinical practices is more accurate for predicting mortality than RDW alone.

Albumin is a vital protein to modulate oncotic pressure [24], and a previous study demonstrated that its concentration correlated with the permeability of pulmonary vessels in critically ill patients [25]. Furthermore, several studies have revealed that low serum albumin concentration had the effect on increased mortality in those with pneumonia, sepsis or cancer [26–30]. Arterial lactate/albumin ratio, combined index, is associated with mortality in critically ill patients with sepsis or septic shock, in some studies [31–33]. A recent study showed that the albumin-RDW score is the independent factor of 90-day mortality in patients with severe community-acquired pneumonia [34]. The clinical relevance of the RDW/albumin ratio in critically ill patients with pneumonia that underwent invasive mechanical ventilation (IMV) still remains to be fully elucidated. In addition, this ratio has not been compared with other combined indexes used to predict mortality.

This study aimed to assess the relationship between the RDW/albumin ratio and 28-day mortality and compare this ratio with the lactate/albumin ratio.

2. Materials and Methods

2.1. Patients

Medical records of critically ill patients with pneumonia hospitalized in the medical ICU at a university-affiliated hospital from May 2018 to December 2020 were reviewed, retrospectively. Patients less than 18 years old, with active malignancy, and those who received only non-invasive oxygen therapy, such as high flow nasal cannula oxygen therapy during ICU admission, were excluded for final analysis.

2.2. Data Collection

Baseline characteristics such age, gender, age, body mass index (BMI), and underlying diseases upon ICU admission were obtained. Severity of illness and organ dysfunction at ICU admission were assessed by calculating acute physiology and chronic health evaluation (APACHE) II and sequential organ failure assessment (SOFA) scores. Clinical characteristics including complications and treatment modalities were collected. Laboratory results (white blood cell, hemoglobin, RDW, platelet, D-dimer, urea, albumin, C-reactive protein [CRP], and lactate) were collected. CURB-65 index was calculated to present the severity of pneumonia.

2.3. Study Outcome and Definition

The 28-day mortality rate was the main clinical outcome for this study. Septic shock was defined using sepsis III diagnostic criteria [6], and ARDS met the Berlin definition [35]. The RDW/albumin ratio was produced based on the time of MICU admission and the application of invasive mechanical ventilation. The formula was as follows: RDW (%)
divided by albumin concentration (g/dL). The lactate/albumin ratio was also calculated; lactate (mmol/L) divided by albumin concentration (g/dL).

2.4. Statistical Analysis

Continuous data were presented as the median with interquartile range (IQR) and the Mann–Whitney U test was used for comparison. Non-continuous data were reported as numbers (%) and were compared using Fisher’s exact test and/or the chi-square test. By using a receiver-operating characteristic (ROC) curve and the Youden method, a cut-off value was determined to classify low and high RDW/albumin ratios [36]. Factors associated with 28-day mortality were determined using multiple logistic regression analysis. Factors with significance in univariate analysis were entered in a multivariate analysis using backward stepwise methods. The Kaplan–Meier method and the log-rank test were used to compare the 28-day mortality between low and high RDW/albumin ratio groups. A p-value less than 0.05 was considered statistically significant. All analysis of data were performed using SPSS software version 22.0 (IBM Corp., Armonk, NY, USA) and MedCalc® for Windows, Version 15.22.4 (MedCalc® Software, Ostend, Belgium) and figures were generated using Prism 5.01 (GraphPad Software Inc., San Diego, CA, USA).

3. Results

3.1. Characteristics of the Patients

The median age of 234 patients was 76 years, and 73.1% were men. The 28-day mortality rate was 46.6%. The baseline and clinical characteristics between survivors and non-survivors at 28-days are shown in Table 1. The proportions of male patients and those with chronic liver disease were significantly higher in non-survivors than in survivors. APACHE II and SOFA scores calculated at MICU admission were significantly higher in non-survivors than survivors at 28 days. Clinical presentations of septic shock, ARDS, and acute kidney injury more frequently developed in non-survivors than in survivors.

| Variables                        | Total N = 234 | Survivor N = 125 | Non-Survivors N = 109 | p-Value |
|----------------------------------|---------------|------------------|-----------------------|---------|
| Age, years old                  | 76 (64.8–81)  | 76 (61.5–80)     | 76 (65.5–81)          | 0.323   |
| Gender, male                     | 171 (73.1)    | 83 (66.4)        | 88 (80.7)             | 0.014   |
| BMI, (kg/m²)                     | 20.9 (18.5–23.3) | 21.3 (18.3–23.7) | 20.8 (18.6–23)        | 0.684   |
| Diabetes mellitus                | 95 (40.6)     | 47 (37.6)        | 48 (44)               | 0.317   |
| Chronic kidney disease           | 31 (12.5)     | 16 (12.8)        | 15 (13.8)             | 0.829   |
| Chronic heart failure            | 25 (10.7)     | 13 (10.4)        | 12 (11)               | 0.880   |
| Chronic liver disease            | 28 (12)       | 9 (7.2)          | 19 (17.4)             | 0.016   |
| Cerebrovascular disease          | 49 (20.9)     | 28 (22.4)        | 21 (19.3)             | 0.557   |
| COPD                             | 43 (18.4)     | 27 (21.6)        | 16 (14.7)             | 0.173   |
| ILD                              | 12 (5.1)      | 5 (4)            | 7 (6.4)               | 0.402   |
| APACHE II                        | 24 (19–28)    | 22 (17–25)       | 27 (22–33)            | <0.001  |
| SOFA                             | 11 (8–13)     | 9 (7–11)         | 13 (10–15)            | <0.001  |
| Types of pneumonia               |               |                  |                       |         |
| CAP                              | 117 (50)      | 65 (52)          | 52 (47.7)             | 0.512   |
| Nosocomial pneumonia             | 117 (50)      | 60 (48.1)        | 57 (52.3)             |         |
| Septic shock                     | 178 (76.1)    | 85 (68)          | 93 (85.3)             | 0.002   |
| ARDS                             | 131 (56)      | 58 (46.4)        | 73 (67)               | 0.002   |
| AKI                              | 117 (50)      | 46 (36.8)        | 71 (65.1)             | <0.001  |
| HFNC before IMV                  | 77 (32.9)     | 28 (22.4)        | 49 (45)               | <0.001  |
| RRT                              | 54 (23.1)     | 14 (11.2)        | 40 (36.7)             | <0.001  |
| Prone position                   | 15 (6.4)      | 6 (4.8)          | 9 (8.3)               | 0.282   |
| ECMO                             | 10 (4.3)      | 5 (4)            | 5 (4.6)               | 0.825   |

BMI, body mass index; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease; APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; ARDS, acute respiratory distress syndrome; AKI, acute kidney injury; HFNC, high-flow nasal cannula oxygen therapy; IMV, invasive mechanical ventilation; RRT, renal replacement therapy; ECMO, extracorporeal membrane oxygenation.
Laboratory parameters and their comparisons are shown in Table 2. Concentrations of hemoglobin and albumin were significantly lower in non-survivors than survivors, whereas RDW, platelets, and arterial lactate values were higher. The partial pressure of the oxygen/fractioned inspired oxygen ratio, reflecting oxygenation, was significantly lower in non-survivors than in survivors.

Table 2. Comparisons of laboratory and ventilator values at intubation and mechanical ventilation between survivors and non-survivors at 28 days.

| Variables               | Total | Survivors | Non-Survivors | p-Value |
|-------------------------|-------|-----------|---------------|---------|
| Age                     | N = 234 | N = 125   | N = 109       |         |
| WBC, · 10^3/mm^3        | 13.6 (6.6–20.5) | 13.2 (8–19.1) | 14.1 (5.5–21.9) | 0.994   |
| Hb, g/dL                | 10.9 (9.4–12.2)  | 11.2 (9.9–12.5) | 10.5 (8.9–11.9) | 0.007   |
| RDW, %                  | 14.4 (13.4–15.6) | 14 (13.2–15.2) | 14.9 (13.6–16.2) | 0.008   |
| Platelet, · 10^3/mm^3   | 181 (106–248)   | 190 (143–264)  | 146 (83.5–225.5) | 0.001   |
| D-dimer, ug/mL (n = 175)| 3.6 (1.7–7.3)   | 3.4 (1.6–6.4)  | [90/125] | 3.7 (1.9–8.4) [85/109] | 0.195   |
| Albumin, g/dL           | 26.9 (17.9–42.5) | 23.6 (15.9–39) | 30.7 (21.4–45) | <0.001  |
| CRP, mg/dL              | 5.9 (9.1–25.9) | 14.4 (7.9–25.9) | 18.8 (11.2–26) | 0.141   |
| Lactate,                | 3 (1.8–5.2)    | 2.6 (1.6–4.1)  | 3.6 (2.6–5) | 0.002   |
| P/F ratio               | 140 (102–198.4) | 161.7 (125.7–226.9) | 122.9 (93.2–171.7) | <0.001 |
| CURB-65 score           | 4 (4–5)         | 4 (3–5)        | 5 (4–5)       | <0.001  |
| ≥4                      | 188 (80.3)      | 90 (72)        | 98 (89.9)    | 0.001   |

Table 3. Univariate and multivariate analysis for factors associated with 28-day mortality.

| Variable        | OR  | 95% CI         | p-Value | OR  | 95% CI         | p-Value |
|-----------------|-----|----------------|---------|-----|----------------|---------|
| Age             | 1.018 | 0.997–1.039 | 0.086 | 1.046 | 1.017–1.076 | 0.002   |
| Male gender     | 2.120 | 1.160–3.878 | 0.015 | 2.015 | 0.955–4.248 | 0.066   |
| CLD             | 2.721 | 1.175–6.300 | 0.019 | -     | -             | -       |
| APACHEII        | 1.150 | 1.098–1.205 | <0.001 | -     | -             | -       |
| SOFA            | 1.340 | 1.220–1.471 | <0.001 | 1.280 | 1.151–1.424 | <0.001  |
| ARDS            | 2.342 | 1.376–3.987 | 0.002 | 1.931 | 0.981–3.798 | 0.057   |
| Hb              | 0.848 | 0.746–0.964 | 0.012 | 0.939 | 0.813–1.085 | 0.394   |
| Platelet        | 0.996 | 0.994–0.999 | 0.002 | -     | -             | -       |
| Lactate         | 1.187 | 1.084–1.299 | <0.001 | -     | -             | -       |
| P/F ratio       | 0.991 | 0.987–0.995 | <0.001 | 0.993 | 0.988–0.999 | 0.03    |
| RDW/Albumin ratio | 1.545 | 1.282–1.862 | <0.001 | 1.379 | 1.103–1.723 | 0.005   |

3.2. RDW/Albumin Ratio and Factors Related to a 28-Day Mortality

The median RDW/albumin ratio of all patients was 5.2 [interquartile range (IQR), 4.3–6.4]. Non-survivors had a significantly higher median RDW/albumin ratio than survivors [5.8 (IQR, 4.8–7.1) vs. 4.8 (IQR, 3.9–5.6), p < 0.001].

Univariate and multivariate logistic analyses for evaluation of factors related to a 28-day mortality are presented in Table 3. In the univariate analysis, the male gender, chronic liver disease, APACHE II and SOFA score, ARDS, hemoglobin, platelet, lactate, partial pressure of the oxygen/fractioned inspired oxygen ratio and the RDW/albumin ratio were significantly associated with a 28-day mortality. In the multivariate analysis, a high RDW/albumin ratio (odds ratio [OR] 1.379, 95% confidence interval [CI] 1.103–1.723, p = 0.005) was associated with 28-day mortality, along with old age, high SOFA score, and lower partial pressure of oxygen/fractioned inspired oxygen ratio.
3.3. Determination of the Cut-Off Value for RDW/Albumin Ratio, and the Comparison with Lactate/Albumin Ratio for Discrimination of 28-Day Mortality

The cut-off value for the RDW/albumin ratio was 5.73 (52.3% sensitivity and 79.2% specificity) to discriminate 28-day mortality, and the area under the ROC (AUROC) curve was 0.688 (95% CI: 0.625–0.747, p < 0.001). The cut-off value for the lactate/albumin ratio was 1.92 (39.4% sensitivity and 87.2% specificity) to discern 28-day mortality, and the AUROC was 0.658 (95% CI: 0.593–0.719, p < 0.001) (Figure 1). There was no difference in the ability of the RDW/albumin and lactate/albumin ratios in predicting 28-day mortality (p = 0.486). When the two groups were divided according to the RDW/albumin ratio cut-off, patients with a ratio >5.73 had a higher survival rate (Figure 2, p < 0.001).

![Figure 1](image1.png)  
**Figure 1.** The comparison of the AUROCs. (RDW/Albumin ratio, 0.694 and lactate/albumin ratio, 0.664, p = 0.455).

![Figure 2](image2.png)  
**Figure 2.** Kaplan–Meier survival curve at 28 days, between non-survivors and survivors with pneumonia receiving invasive mechanical ventilation (p < 0.001).
4. Discussion

The present study revealed that the median RDW/albumin ratio was significantly higher in critically ill patients with pneumonia who died at 28 days after receiving IMV. The increased RDW/albumin ratio was associated with 28-day mortality in the multivariate analysis, which suggests that a high RDW/albumin ratio may be a potential predictor of 28-day mortality in these patients. Furthermore, the RDW/albumin ratio was comparable to the lactate/albumin ratio in predicting 28-day mortality. Patients with an RDW/albumin >5.73 had a significantly higher 28-day mortality rate than those with an RDW/albumin ratio ≤5.73.

Pneumonia is a commonly encountered lower respiratory tract disease, and contributes considerably to hospitalization and health burdens [1,2]. Severe conditions such as septic shock or acute respiratory failure develop [4–6,33], and these conditions typically require ICU admission and intensive management including fluid, vasopressor infusion or mechanical ventilation [7,37]. Inflammation is initiated by the host-pathogen interaction, and is a major pathogenesis for patients to develop fatal outcomes [11–13]. Therefore, the use of agents to eradicate the pathogens and the recognition and control of inflammation is crucial to improve clinical outcomes in critically ill patients with pneumonia who are receiving IMV. Based on the inflammatory response as a major mechanism, identification of new inflammatory markers or repurposing of the previously known indices could be valuable to determine severity or predict clinical outcomes [14,15].

The RDW expresses the variation of red blood cell size, and is known to increase in response to inflammatory stimuli [16]. Increased RDW has been associated with poor outcomes in many clinical situations, such as pneumonia [38], sepsis/septic shock [19], ARDS [39], cardiovascular diseases [40], surgery [41], and malignant conditions [18]. RDW is a marker to reflect the variability in red blood cell size and its increase is called anisocytosis. Several conditions, such as inflammatory reaction, are associated with increased RDW [16]. The RDW has been related to outcomes in various clinical conditions [17–20], including critical illness [21]. Elaborated mechanisms for increased RDW in critically ill conditions, including severe pneumonia or sepsis, remain to be determined; inflammation is induced to produce the circulation of premature erythrocytes from the bone marrow [22]. In addition, oxidative stress produces reactive oxygen species (ROS) excessively, which also stimulate erythropoiesis, leading to anisocytosis and increased RDW [23]. There are a few studies that suggest the combination of RDW and other feasible markers in clinical practice will predict mortality more efficiently than RDW alone.

Serum albumin is a laboratory value, routinely measured from blood in hospitalized patients; it plays many roles, including in acute phase reactions [42] and in the control of oncotic pressure [24,25]. Furthermore, several studies have indicated that that its concentration was a prognostic factor in patients with pneumonia or sepsis [26,28–30]. As therapeutic role, in SAFE study, the administration of albumin has similar outcomes compared to saline in the ICU. Furthermore, in this study, patients receiving albumin had less fluid balance than those receiving saline [43]. Other studies have shown that the replacement of albumin in hypoalbumic critically ill patients reduced the severity of organ dysfunction [44].

In a post hoc analysis of ALBIOS study, albumin replacement added to crystalloid showed more hemodynamic stability than crystalloid alone, in patients with severe sepsis and septic shock [45].

New combined indexes have been developed and investigated for clinical impact on diagnostic or prognostic markers in critically ill patients. The lactate/albumin ratio was reported to be correlated with short-term mortality in patients with sepsis or septic shock [31,33,46]. Lactate is typically measured from arterial blood to predict severity, prognosis, or for treatment monitoring in cases of sepsis/septic shock. However, the relationship between venous and arterial lactate remains controversial [47–49], and it could be difficult to take arterial blood continuously, due to the risk of peripheral arteries in
critical care practices. Consequently, it is not feasible to calculate the lactate/albumin ratio for all critically ill patients.

Considering the feasible measurement from venous blood and the clinical role of RDW on prognosis demonstrated by many studies, the RDW/albumin ratio was applied to evaluate its ability to predict mortality in patients with pneumonia receiving IMV. In the previous study of patients with ARDS, RDW/albumin was associated with 60-day mortality [50]. Chen et al. reported that the albumin-RDW score derived from the ROC curve was the independent risk factor of 90-day mortality in patients with severe community-acquired pneumonia [34]. This study supports the usefulness of the combined index of RDW and albumin in pneumonia.

The present study showed that high RDW/albumin was associated with increased 28-day mortality in patients with pneumonia. This result suggests that RDW/albumin plays a role in a new index of predicting mortality in patients with pneumonia receiving IMV. In addition, there was no significant difference between the RDW/albumin and lactate/albumin ratio, in predicting 28-day mortality. This finding suggests that the RDW/albumin ratio may be as useful as the lactate/albumin ratio.

There are several limitations in this study. First, considering the retrospective design conducted in a single center, and the limitation of the sampling analysis, selection and sampling bias cannot be excluded. Therefore, the results should be interpreted cautiously when applied to other clinical settings. Accurate analysis of sample size in the future prospective study is needed to overcome the limitations of our results. Second, the RDW/albumin ratio at a single time point was calculated, and therefore the clinical implication of later time-points cannot be excluded. Whether changes in the RDW/albumin ratio will impact the mortality of these patients requires further studies.

In conclusion, RDW/albumin ratio is easily calculated in clinical practice. A high RDW/albumin ratio in critically ill patients with pneumonia receiving IMV is associated with 28-day mortality, and there is a similar predictability level for the lactate/albumin ratio, which is a useful combined index of critical illness. The RDW/albumin ratio has the potential of a repurposed index to predict the outcome of critically ill patients with pneumonia receiving invasive mechanical ventilation in the ICU.

Author Contributions: J.-W.Y.: Conceptualization; formal analysis; investigation; methodology; writing—original draft; writing—review and editing.; J.H.J.: formal analysis; methodology; supervision; writing—review and editing; M.H.: formal analysis; methodology; supervision; writing—review and editing; S.J.L.: formal analysis; methodology; supervision; writing review and editing.; Y.Y.J.: formal analysis; methodology; supervision; writing—review and editing; J.D.L.: formal analysis; methodology; supervision; writing—review and editing. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Gyeongsang National University Hospital (IRB No. 2021-03-015, approval date: 30 March 2021).

Informed Consent Statement: Informed consent from patients or their relatives was waived because of the retrospective analysis.

Data Availability Statement: Data are available upon reasonable request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Corrado, R.E.; Lee, D.; Lucero, D.E.; Varma, J.K.; Vora, N.M. Burden of Adult Community-acquired, Health-care-Associated, Hospital-Acquired, and Ventilator-Associated Pneumonia: New York City, 2010 to 2014. Chest 2017, 152, 930–942. [CrossRef] [PubMed]
2. Troeger, C.; Blacker, B.; Khalil, I.A.; Rao, P.C.; Cao, J.; Zimsen, S.R.; Albertson, S.B.; Deshpande, A.; Farag, T.; Abebe, Z.; et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect. Dis. 2018, 18, 1191–1210. [CrossRef]
3. Jain, S.; Self, W.H.; Wunderink, R.G.; Fakhran, S.; Balk, R.; Bramley, A.M.; Reed, C.; Grijalva, C.G.; Anderson, E.J.; Courtney, D.M.; et al. Community-Acquired Pneumonia Requiring Hospitalization among US Adults. *New Engl. J. Med.* 2015, 373, 415–427. [CrossRef] [PubMed]

4. Jeon, K.; Na, S.J.; Oh, D.K.; Park, S.; Choi, E.Y.; Kim, S.C.; Seong, G.M.; Heo, J.; Chang, Y.; Kwack, W.G.; et al. Characteristics, management and clinical outcomes of patients with sepsis: A multicenter cohort study in Korea. *Acute Crit. Care* 2019, 34, 179–191. [CrossRef] [PubMed]

5. Cilloniz, C.; Ferrer, M.; Liapikou, A.; Garcia-Vidal, C.; Gabarrus, A.; Ceccato, A.; De La Bellacasa, J.P.; Blasi, F.; Torres, A. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. *Eur. Respir. J.* 2018, 51, 1702215. [CrossRef]

6. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.-D.; Coopersmith, C.C.M.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016, 315, 801–810. [CrossRef] [PubMed]

7. Fan, E.; Del Sorbo, L.; Goligher, E.C.; Hodgson, C.L.; Munshi, L.; Walkey, A.J.; Adhikari, N.K.J.; Amato, M.B.P.; Branson, R.; Brower, R.G.; et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. *Am. J. Respir. Crit. Care Med.* 2017, 195, 1253–1263. [CrossRef]

8. Blot, S.; Koulenti, D.; Dimopoulos, G.; Martin, C.; Komnos, A.; Krueger, W.A.; Spina, G.; Armaganidis, A.; Rello, J. Prevalence, Risk Factors, and Mortality for Ventilator-Associated Pneumonia in Middle-Aged, Old, and Very Old Critically Ill Patients*. *Crit. Care Med.* 2014, 42, 601–609. [CrossRef] [PubMed]

9. Ferrer, M.; Travieso, C.; Cilloniz, C.; Gabarrus, A.; Ranzani, O.T.; Polverino, E.; Liapikou, A.; Blasi, F.; Torres, A. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. *PLoS ONE* 2018, 13, e0191721. [CrossRef] [PubMed]

10. Cavallazzi, R.; Furmanek, S.; Arnold, F.W.; Beavin, L.A.; Wunderink, R.G.; Niederman, M.S.; Ramirez, J.A. The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States. *Chest* 2020, 158, 1008–1016. [CrossRef] [PubMed]

11. Mizgerd, J.P. Respiratory Infection and the Impact of Pulmonary Immunity on Lung Health and Disease. *Am. J. Respir. Crit. Care Med.* 2012, 186, 824–829. [CrossRef] [PubMed]

12. Torres, A.; Sibila, O.; Ferrer, M.; Mendendez, R.; Mensa, J.; Gabarrus, A.; Sellares, J.; Restrepo, M.; Anzueto, A.; Niederman, N.; et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. *Acute Crit. Care* 2015, 46, 677–686. [CrossRef]

13. Mizgerd, J.P. Inflammation and Pneumonia: Why Are Some More Susceptible than Others? *Clin. Chest Med.* 2018, 39, 669–676. [CrossRef]

14. Sungurlu, S.; Balk, R.A. The Role of Biomarkers in the Diagnosis and Management of Pneumonia. *Clin. Chest Med.* 2018, 39, 691–701. [CrossRef]

15. Saleh, M.A.; van de Garde, E.M.; van Hasselt, J.C. Host-response biomarkers for the diagnosis of bacterial respiratory tract infections. *Clin. Chem. Lab. Med.* 2019, 57, 442–451. [CrossRef] [PubMed]

16. Salvagno, G.L.; Sanchis-Gomar, F.; Picanza, A.; Lippi, G. Red blood cell distribution width: A simple parameter with multiple clinical applications. *Crit. Rev. Clin. Lab. Sci.* 2015, 52, 86–105. [CrossRef] [PubMed]

17. Zhou, X.-Y.; Chen, H.-L.; Ni, S.-S. Red cell distribution width in predicting 30-day mortality in patients with pulmonary embolism. *Clin. Chest Med.* 2015, 36, 197–201. [CrossRef]

18. Hu, L.; Li, M.; Ding, Y.; Pu, L.; Liu, J.; Xie, J.; Cabanero, M.; Li, J.; Xiang, R.; Xiong, S. Prognostic value of RDW in cancers: A systematic review and meta-analysis. *Oncotarget* 2016, 8, 16027–16035. [CrossRef]

19. Kim, C.H.; Park, J.T.; Kim, E.J.; Han, J.H.; Han, J.S.; Choi, J.Y.; Han, S.H.; Yoo, T.-H.; Kim, Y.S.; Kang, S.-W.; et al. An increase in red blood cell distribution width from baseline predicts mortality in patients with severe sepsis or septic shock. *Crit. Care* 2013, 17, R282. [CrossRef]

20. Nathan, S.D.; Brown, A.W.; Reffett, T.R.; Shlobin, O.A.; Ahmad, S.; Weir, N.; Sheridan, M.J. The red cell distribution width as a prognostic indicator in idiopathic pulmonary fibrosis. *Chest* 2012, 143, 1692–1698. [CrossRef]

21. Bazick, H.S.; Chang, D.; Mahadevappa, K.; Gibbons, F.K.; Christopher, K.B. Red cell distribution width and all-cause mortality in critically ill patients*. *Crit. Care Med.* 2011, 39, 1913–1921. [CrossRef]

22. Bateman, R.M.; Sharpe, M.D.; Singer, M.; Ellis, C.G. The Effect of Sepsis on the Erythrocyte. *Int. J. Mol. Sci.* 2017, 18, 1932. [CrossRef]

23. Friedman, J.S.; Lopez, M.F.; Fleming, M.; Rivera, A.; Martin, F.M.; Welsh, M.L.; Boyd, A.; Doctrow, S.R.; Burakoff, S.J. SOD2-deficiency anemia: Protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness. *Blood* 2004, 104, 2565–2573. [CrossRef] [PubMed]

24. Quinlan, G.J.; Martin, G.S.; Evans, T.W. Albumin: Biochemical properties and therapeutic potential. *Hepatology* 2005, 41, 1211–1219. [CrossRef]

25. Aman, J.; van der Heijden, M.; van Lingen, A.; Gibbes, A.R.; van Nieuw Amerongen, G.P.; van Hinsbergh, V.W.; Groeneveld, A.J. Plasma protein levels are markers of pulmonary vascular permeability and degree of lung injury in critically ill patients with or at risk for acute lung injury/acute respiratory distress syndrome. *Crit. Care Med.* 2011, 39, 89–97. [CrossRef] [PubMed]
26. Lee, J.H.; Kim, J.; Kim, K.; Jo, Y.H.; Rhee, J.; Kim, T.Y.; Na, S.H.; Hwang, S.S. Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia. J. Crit. Care 2011, 26, 287–294. [CrossRef]

27. Gupta, D.; Lis, C.G. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr. J. 2010, 9, 69. [CrossRef]

28. Zhao, L.; Bao, J.; Shang, Y.; Yin, L.; Yu, Y.; Xie, Y.; Chen, L.; Zheng, Y.; Xu, Y.; Gao, Z. The prognostic value of serum albumin levels and respiratory rate for community-acquired pneumonia: A prospective, multi-center study. PLoS ONE 2021, 16, e0248002. [CrossRef] [PubMed]

29. Takegawa, R.; Kabata, D.; Shimizu, K.; Hisano, S.; Ogura, H.; Shintani, A.; Shimazu, T. Serum albumin as a risk factor for death in patients with prolonged sepsis: An observational study. J. Crit. Care 2019, 51, 139–144. [CrossRef]

30. Yin, M.; Si, L.; Qin, W.; Li, C.; Zhang, J.; Yang, H.; Han, H.; Zhang, F.; Ding, S.; Zhou, M.; et al. Predictive Value of Serum Albumin Level for the Prognosis of Severe Sepsis Without Exogenous Human Albumin Administration: A Prospectvie Cohort Study. J. Intensive Care Med. 2016, 33, 687–694. [CrossRef]

31. Shin, J.; Hwang, S.Y.; Jo, I.J.; Kim, W.Y.; Ryoo, S.M.; Kang, G.H.; Kim, K.; Jo, Y.H.; Chung, S.P.; Joo, Y.S.; et al. Prognostic Value of The Lactate/Albumin Ratio for Predicting 28-Day Mortality in Critically ILL Sepsis Patients. Shock 2018, 50, 545–550. [CrossRef]

32. Gharipour, A.; Razavi, R.; Gharipour, M.; Mukasa, D. Lactate/albumin ratio: An early prognostic marker in critically ill patients. Am. J. Emerg. Med. 2020, 38, 2088–2095. [CrossRef]

33. Li, N.; Zhou, H.; Tang, Q. Red Blood Cell Distribution Width: A Novel Predictive Indicator for Cardiovascular and Cerebrovascular Diseases. Int. J. Mol. Sci. 2017, 18, 304–377. [CrossRef]

34. Wang, B.; Chen, G.; Cao, Y.; Xue, J.; Li, J.; Wu, Y. Correlation of lactate/albumin ratio level to organ failure and mortality in severe sepsis and septic shock. J. Crit. Care 2015, 30, 271–275. [CrossRef] [PubMed]

35. Chen, L.; Lu, X.Y.; Zhu, C.Q. Prognostic value of albumin-red cell distribution width score in patients with severe community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 2020, 9, 799–765. [CrossRef]

36. Force, A.D.; Ranieri, V.M.; Rubenfeld, G.D.; Thompson, B.T.; Ferguson, N.; Caldwell, E.; Fan, E.; Camporota, L.; Slutsky, A.S. Acute respiratory distress syndrome: The Berlin Definition. JAMA 2012, 307, 2526–2533. [CrossRef]

37. Youden, W.J. Index for rating diagnostic tests. Cancer 1950, 3, 32–35. [CrossRef]

38. Rhodes, A.A.; Evans, L.E.; Alhazzani, W.; Levy, M.M.; Antonelli, M.; Ferrer, R.; Kumar, A.; Sev埼ansky, J.E.; Sprung, C.L.; Nunnally, M.E.; et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit. Care Med. 2017, 43, 304–377. [CrossRef]

39. Lee, J.H.; Chung, H.J.; Kim, K.; Jo, Y.H.; Rhee, J.E.; Kim, Y.J.; Kang, K.W. Red cell distribution width as a prognostic marker in patients with community-acquired pneumonia. Am. J. Emerg. Med. 2013, 31, 72–79. [CrossRef] [PubMed]

40. Wang, B.; Gong, Y.; Ying, B.; Cheng, B. Relation between Red Cell Distribution Width and Mortality in Critically Ill Patients with Acute Respiratory Distress Syndrome. Blood Res. Int. 2019, 2019, 1942078. [CrossRef]

41. Li, N.; Zhou, H.; Tang, Q. Red Blood Cell Distribution Width: A Novel Predictive Indicator for Cardiovascular and Cerebrovascular Diseases. Dis. Markers 2017, 2017, 7089493. [CrossRef] [PubMed]

42. Hirahara, N.; Tajima, Y.; Fuji, Y.; Kaji, S.; Yamamoto, T.; Hyakudomi, R.; Taniura, T.; Kawabata, Y. Comprehensive Analysis of Red Blood Cell Distribution Width as a Preoperative Prognostic Predictor in Gastric Cancer. Anticancer Res. 2019, 39, 3121–3130. [CrossRef] [PubMed]

43. Gabay, C.; Kushner, I. Acute-Phase Proteins and Other Systemic Responses to Inflammation. N. Engl. J. Med. 1999, 340, 448–454. [CrossRef]

44. Finfer, S.; Bellomo, R.; Boyce, N.; French, J.; Myburgh, J.; Norton, R. A Comparison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit. N. Engl. J. Med. 2004, 350, 2247–2256. [CrossRef]

45. Dubois, M.-J.; E A Orellana Jimenez, C.; Melot, C.; De Backer, D.; Berre, J.; Leeman, M.; Brimioulle, S.; Appoloni, O.; Creteur, J.; Vincent, J.-L. Albumin administration organ function in critically ill hypoalbuminemic patients: A prospective, randomized, pilot study*. Crit. Care Med. 2006, 34, 2536–2540. [CrossRef]

46. Caironi, P.; Tognoni, G.; Masson, S.; Fumagalli, R.; Pesenti, A.; Romero, M.; Fanizza, C.; Caspani, L.; Faenza, S.; Grasselli, G.; et al. Albumin Replacement in Patients with Severe Sepsis or Septic Shock. N. Engl. J. Med. 2014, 370, 1412–1421. [CrossRef]

47. Lichtener, M.; Wernerly, B.; Ohnewein, B.; Franz, M.; Kabisch, B.; Muessig, J.; Masyuk, M.; Lauten, A.; Schulze, P.C.; Hoppe, U.C.; et al. The Lactate/Albumin Ratio: A Valuable Tool for Risk Stratification in Septic Patients Admitted to ICU. Int. J. Mol. Sci. 2017, 18, 1983. [CrossRef]

48. Van Tienhoven, A.J.; van Beers, C.A.J.; Siegert, C.E.H. Agreement between arterial and peripheral venous lactate levels in the ED: A systematic review. Am. J. Emerg. Med. 2019, 37, 746–750. [CrossRef] [PubMed]

49. Mahmoodpoor, A.; Shadvar, K.; Saneie, S.; Golzari, S.E.; Parthvi, R.; Hamishehkar, H.; Nader, N.D. Arterial vs venous lactate: Correlation and predictive value of mortality of patients with sepsis during early resuscitation phase. J. Crit. Care 2020, 58, 118–124. [CrossRef] [PubMed]

50. Theerawit, P.; Na Petvicharn, C.; Tangsajarivijit, V.; Sutherasan, Y. The Correlation Between Arterial Lactate and Venous Lactate in Patients With Sepsis and Septic Shock. J. Intensive Care Med. 2018, 33, 116–120. [CrossRef]